Tuesday, September 8, 2009

H1N1 Vaccine Manufacturers: Stocks That May Soar

Here is a list of H1N1 vaccine (swine flu shot) manufacturers. These are expected to benefit from the purchases of hundreds of millions of dosages by governments around the world.

Note that this is purely from a stock market point of view. These companies may become quite popular and their shares may soar. There is nothing stated here about the safety of the vaccines.


Novartis is the Swiss company we reported a few weeks ago was the first to have a successful H1N1 vaccine. It expects to have a vaccine ready by October. It has several orders for H1N1 vaccines.


Glaxo is testing a H1N1 flu vaccine in humans and expects to start giving the results to government agencies in September. It has won orders for H1N1 swine flu vaccine from nine governments, for a total number of doses ordered to 300+ million, with more orders still to come. Potentai windfall: $3 billion in the next six months or so.


SNY is one of the world leaders in flu shots and has received large orders from the U.S. and France, and it is in discussions with more than 30 countries about supplies.

It has a $250 million deal to provide the U.S. with the swine flu antigen in bulk.


Astra had an initial $90 million order from the U.S. Its vaccine technology is different from traditional injectable flu shots in that it is a mist sprayed into the nose, making it far more comfortable to apply.


China's SVA was the first company worldwide to complete clinical trials for an H1N1 vaccine, and that received approval from Chinese health authorities.


Baxter completed its first commercial batches of H1N1 vaccine made using a cell culture process designed to be faster than traditional chicken egg-based vaccine production methods. It has supply contracts with several countries (Britain, Ireland and New Zealand). It said it could not take on additional orders.


Inovio claims its DNA-based H1N1 flu vaccines provide protection against the swine flu strain in pigs and mice. It expects to begin manufacturing vaccine supplies for H1N1 clinical studies soon (this was August) hut it does not yet have the U.S. approval to begin human trials.


U.S. biotech company Novavax has a new kind of influenza vaccine that works against the swine flu virus in animals. It would have to get approval from the U.S. Food and Drug Administration before it could test the new vaccine in people and years of testing are likely to be required before such a new formulation could be widely used in humans


Australia's CSL trades as an over the counter stock, it has been in mass production of H1N1 vaccine for several weeks, completed a first batch of 2 million shots and is producing 1-1.5 million doses per week until it fills all orders.

It has received $180 million contract from the U.S. for H1N1 flu vaccine and an order for 21 million doses from Australia. It expected to book sales of about $250 million from swine flu vaccines in the year to 2010.


Belgium's Solvay said that production of a cell-based H1N1 vaccine for clinical studies would start in August.

HUALAN BIOLOGICAL This Chinese company received the go-head from a Chinese panel of experts for an H1N1 vaccine.


South Korea's Green Cross can be expected to benefit from the $155M set aside for H1N1 vaccine preparations.

Stumble Upon Toolbar


vince52 said...

You state thate that NVAX needs FDA approval before it will have a saleable product. Not so. It has trials ongoing in India and Mexico, and could start selling product in 1Q 2010.

Josue said...
This comment has been removed by a blog administrator.

Financial TV

Blog Archive

// adding Google analytics